The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Kirske David since 2022.
This trader's CIK number is 1276750.
At the time of last reporting, Kirske David was the EVP, Chief Financial Officer of Cti Biopharma Corp. (stock ticker symbol CTIC).
Also see all insider trading activities at Cti Biopharma Corp.
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2023 | CTIC | 0 | $0 | 54,042 | $324,618 | 54,042 | $51,284 |
| 2022 | CTIC | 0 | $0 | 374,674 | $2,264,297 | 374,674 | $427,623 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2023-01-03 | CTIC | Option Ex | 27,021 | .95 | 25,642 |
| 2022-12-29 | CTIC | Option Ex | 13,174 | .95 | 12,502 |
| 2022-12-30 | CTIC | Option Ex | 13,847 | .95 | 13,140 |
| 2023-01-03 | CTIC | Sale | 27,021 | 6.01 | 162,423 |
| 2022-12-29 | CTIC | Sale | 13,174 | 6.00 | 79,044 |
| 2022-12-30 | CTIC | Sale | 13,847 | 6.00 | 83,151 |
| 2022-09-29 | CTIC | Sale | 900 | 6.00 | 5,404 |
| 2022-10-03 | CTIC | Sale | 300 | 6.25 | 1,875 |
| 2022-09-30 | CTIC | Option Ex | 139,841 | .95 | 132,709 |
| 2022-09-29 | CTIC | Option Ex | 900 | .95 | 854 |
| 2022-10-03 | CTIC | Option Ex | 300 | .95 | 284 |
| 2022-09-30 | CTIC | Sale | 139,841 | 6.05 | 845,618 |
| 2022-10-03 | CTIC | Option Ex | 300 | .95 | 284 |
| 2022-09-29 | CTIC | Option Ex | 900 | .95 | 854 |
| 2022-09-30 | CTIC | Option Ex | 139,841 | .95 | 132,709 |
| 2022-10-03 | CTIC | Sale | 300 | 6.25 | 1,875 |
| 2022-09-29 | CTIC | Sale | 900 | 6.00 | 5,404 |
| 2022-09-30 | CTIC | Sale | 139,841 | 6.05 | 845,618 |
| 2022-09-16 | CTIC | Sale | 22,592 | 6.02 | 136,003 |
| 2022-09-16 | CTIC | Option Ex | 22,592 | .95 | 21,439 |
| 2022-06-17 | CTIC | Sale | 60,000 | 6.12 | 367,500 |
| 2022-06-17 | CTIC | Option Ex | 60,000 | 2.15 | 129,000 |
| 2022-06-14 | CTIC | Option Ex | 10,000 | .95 | 9,490 |
| 2022-06-14 | CTIC | Sale | 10,000 | 5.50 | 55,000 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Kirske David (EVP, Chief Financial Officer of Cti Biopharma Corp at the time of this reporting) see the Securities and Exchange Commission (SEC) website.